Veracyte CAO exercises options, sells 24K shares

Rhea-AI Filing Summary

VERACYTE, INC. Vice President and Chief Accounting Officer Jonathan Wygant reported an exercise-and-sell transaction in company stock. On May 22, 2026, he exercised stock options for 24,000 shares of common stock at $24.80 per share, then sold 24,000 shares of common stock in an open-market sale at a weighted average price of $45.401 per share, with individual sale prices ranging from $45.07 to $45.69. Following these transactions, he directly owns 45,434 shares of Veracyte common stock. The option exercised is reported as fully vested and, after exercise, no remaining shares from that option grant are outstanding.

Insider Trade Summary

Exercise and Sale: 24,000 shares ($494K approx. pre-tax spread)

Exercise and Sale 3 txns

Insider Wygant Jonathan

Role VP, Chief Accounting Officer

Sold 24,000 shs ($1.09M)

Approx. gross sale proceeds $1.09M

Approx. exercise cost $595K

Approx. pre-tax spread $494K

Type	Security	Shares	Price	Value
Exercise	Stock Option (right to buy)	24,000	$0.00	$0.00
Exercise	Common Stock	24,000	$24.80	$595K
Sale	Common Stock	24,000	$45.401	$1.09M

Holdings After Transaction: Stock Option (right to buy) — 0 contracts (Direct); Common Stock — 45,434 shares (Direct)

Footnotes (2)

1. F1. Represents weighted average sales price. Sale prices for the transactions range from $45.07 to $45.69. Detailed information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or a shareholder upon request.
2. F2. The option is fully vested.

Key Figures

Shares sold: 24,000 shares Weighted average sale price: $45.401 per share Sale price range: $45.07 to $45.69 per share +3 more

6 metrics

Shares sold 24,000 shares Common stock sold in open-market transaction on May 22, 2026

Weighted average sale price $45.401 per share Average price for 24,000 Veracyte common shares sold

Sale price range $45.07 to $45.69 per share Range of individual sale prices disclosed in footnote

Options exercised 24,000 shares at $24.80 Stock option exercise converting derivative into common stock

Post-transaction holdings 45,434 shares Common shares directly owned after transactions

Option expiration February 22, 2032 Expiration date of the exercised stock option grant

Key Terms

open-market sale, Stock Option (right to buy), weighted average sales price, derivative exercise/conversion

4 terms

open-market sale financial

"transaction_action shows an open-market sale of common stock"

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

Stock Option (right to buy) financial

"security_title lists Stock Option (right to buy) as a derivative"

weighted average sales price financial

"footnote states it represents a weighted average sales price"

derivative exercise/conversion financial

"transaction_action describes a derivative exercise/conversion"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Veracyte (VCYT) report for Jonathan Wygant?

Veracyte reported that VP and Chief Accounting Officer Jonathan Wygant exercised options for 24,000 shares and sold 24,000 common shares in an open-market transaction on May 22, 2026, according to a Form 4 insider trading filing.

How many Veracyte (VCYT) shares did Jonathan Wygant sell and at what price?

Jonathan Wygant sold 24,000 shares of Veracyte common stock in an open-market sale at a weighted average price of $45.401 per share, with individual sale prices ranging from $45.07 to $45.69, as disclosed in the Form 4 filing.

What stock options did Jonathan Wygant exercise in the Veracyte (VCYT) Form 4?

He exercised a fully vested stock option covering 24,000 underlying shares of Veracyte common stock at an exercise price of $24.80 per share. After this derivative exercise, the reported option position shows zero remaining shares from that grant outstanding.

How many Veracyte (VCYT) shares does Jonathan Wygant own after the transaction?

Following the May 22, 2026 transactions, Jonathan Wygant directly owns 45,434 shares of Veracyte common stock. This post-transaction holding reflects the option exercise and subsequent sale reported in the Form 4 insider trading disclosure.

Was the Veracyte (VCYT) insider sale by Jonathan Wygant an open-market transaction?

Yes. The Form 4 describes the transaction as an open-market sale of common stock, coded as “S,” with a weighted average sale price and a detailed price range from $45.07 to $45.69 available upon request.

What does the weighted average sale price mean in the Veracyte (VCYT) Form 4?

The weighted average price of $45.401 per share reflects multiple sale transactions between $45.07 and $45.69. The filing notes that detailed share counts at each separate price level are available from the company, the insider, or the SEC upon request.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 05/27/2026 - 04:19 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Wygant Jonathan

(Last) (First) (Middle)

6000 SHORELINE COURT, SUITE 300

(Street)

SOUTH SAN FRANCISCO CALIFORNIA 94080

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
VERACYTE, INC. [ VCYT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	VP, Chief Accounting Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/22/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	05/22/2026		M		24,000	A	$24.8	69,434	D
Common Stock	05/22/2026		S		24,000	D	$45.401(1)	45,434	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$24.8	05/22/2026		M			24,000	(2)	02/22/2032	Common Stock	24,000	$0	0	D

Explanation of Responses:

1. Represents weighted average sales price. Sale prices for the transactions range from $45.07 to $45.69. Detailed information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or a shareholder upon request.

2. The option is fully vested.

Remarks:

	/s/ Jonathan Wygant	05/27/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)